TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24037893
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with TPF regimen (docetaxel 75 mg/m(2), cisplatin 75 mg/m(2), and 5‐fluorouracil 2500 mg/m(2) every 3 weeks for 3 cycles) followed by concurrent chemoradiation (cisplatin 40 mg/m(2) per week with either 3-dimensional conformal radiation therapy or intensity-modulated radiation therapy)
Study: 19517892
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (amisulpride 200 mg)
Study: 19517892
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (amisulpride 200 mg)
Study: 11447776
Drug: Intraarticular administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular administration of high molecular weight sodium hyaluronate (one 20 mg vial/week for 3 weeks)
Study: 15512177
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate 10 mg daily
Study: 7517472
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment with vasoactive compounds
Study: 7517472
Drug: Long-term physical
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term physical exercise (twice for 2 h/week for 24 months)
Study: 7517472
Drug: Intensive therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapeutic regimens using intravenous infusions
Study: 23871729
Drug: G biloba
Approvals — FDA: no, EMA: no, PMDA: no
Description: G biloba
Study: 16933577
Drug: Atorvastatin (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (Group 1)
Study: 15152589
Drug: Epidural preemptive
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural preemptive analgesia with 2 micrograms/kg fentanyl in 0.25% bupivacaine in 10 ml serum saline
Study: 15152589
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 10 ml serum saline 20 minutes before the incision
Study: 11310460
Drug: Intramuscular midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular midazolam (0.4 mg/kg)
Study: 11310460
Drug: Intranasal flumazenil
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal flumazenil (25 microg/kg)
Study: 11310460
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose intramuscular ketamine (2.5 mg/kg)
Study: 3691913
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil (3% solution)
Study: 3691913
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil (5% solution)
Study: 19552097
Drug: Metformin 500mg
Normalized name: METFORMIN 500MG/SITAGLIPTIN 50MG TAB
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 500mg orally 8 hourly daily for initial 3 months, followed by clomiphene 50mg orally once daily for 5 days for subsequent 3 months
Study: 19552097
Drug: Placebo (folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (folic acid 5mg orally once daily for initial 3 months), followed by clomiphene 50mg orally once daily for 5 days for subsequent 3 months
Study: 11148694
Drug: Microchips and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microchips and heat sensors for compliance with amblyopia therapy
Study: 9350166
Drug: Moderate beer
Normalized name: BEER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate beer consumption (330 ml of Maccabee beer, > 20 g of alcohol) for 30 consecutive days
Study: 31615726
Drug: Unpreserved trehalose
Normalized name: Trehalose
DrugBank: Trehalose (DB12310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unpreserved trehalose 3%, hyaluronic acid 0.15%, carbomer 0.25% (THHA, Thealoz Duo Gel)
Study: 30285758
Drug: internet delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet delivered cognitive behaviour therapy (iCBT) plus treatment as usual (TAU)
Study: 27180023
Drug: Midazolam (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.04 mg/kg) and propofol (1.0 μg/mL)
Study: 27180023
Drug: Propofol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5 μg/mL)
Study: 24630053
Drug: Randomized treatment
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized treatment assignment
Study: 20724140
Drug: 5FU, folinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FU, folinic acid and cisplatin combination followed by gemcitabine (Arm A)
Study: 20724140
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (Arm A and Arm B)
Study: 16167420
Drug: Clindamycin/benzoyl peroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin/benzoyl peroxide gel (combination formulation)
Study: 16167420
Drug: Clindamycin/benzoyl peroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin/benzoyl peroxide gel + tretinoin gel + clindamycin gel
Study: 16167420
Drug: Clindamycin/benzoyl peroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin/benzoyl peroxide gel
Study: 12934183
Drug: Virosome-formulated, aluminum-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosome-formulated, aluminum-free inactivated HAV vaccine
Study: 30463813
Drug: atorvastatin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin group
Study: 22129843
Drug: Psilocybin 5
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin 5 mg/70 kg
Study: 22129843
Drug: Psilocybin 10
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin 10 mg/70 kg
Study: 22129843
Drug: Psilocybin 0
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin 0 mg/70 kg (placebo)
Study: 16643550
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan 3 mg (1 mL)
Study: 12893646
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 800 microg BUD via Turbuhaler
Study: 12893646
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 750 microg FP via Diskus
Study: 12893646
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 200 microg BUD
Study: 12893646
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 200 microg fluticasone dipropionate
Study: 12893646
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of BUD and FP on the same day
Study: 1552406
Drug: Depakote Sprinkle
Normalized name: Depakote Sprinkles
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Depakote Sprinkle capsules
Study: 1552406
Drug: Depakene syrup
Normalized name: Depakote
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Depakene syrup
Study: 22706026
Drug: Trans-triepitopic antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-triepitopic antibody fusions
Study: 20331585
Drug: Lymphocyte immunotherapy
Normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphocyte immunotherapy
Study: 18558169
Drug: Ceftriaxone and
Normalized name: Ceftriaxone and sulbactam only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone and metronidazole (CM) - 2 total doses per day
Study: 18558169
Drug: Ampicillin, gentamicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin, gentamicin, and clindamycin (AGC) - 11 total doses per day
Study: 6151243
Drug: Trimipramine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine (various doses)
Study: 6151243
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg trimipramine in the evening
Study: 24088617
Drug: Weight Management
Normalized name: Estroven Weight Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight Management (WM) intervention including education about regular daily weight monitoring and coping skills, with a WM booklet and scheduled telephone visits
Study: 19874314
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections at the temporal hairline
Study: 19874314
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections at the temporal hairline plus extra injections at each temporal line
Study: 18037223
Drug: Epo‐alpha (40,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epo‐alpha (40,000 IU intravenously each injection, 5 doses within 48 hours)
Study: 11069340
Drug: Alfentanil 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 0.25 mg with bupivacaine 2.5 mg intrathecally
Study: 11069340
Drug: Alfentanil 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 0.25 mg intrathecally
Study: 8627434
Drug: Indomethacin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.1 mg/kg per dose, administered less than 24 hours after birth and again every 24 hours for six doses)
Study: 4051254
Drug: Blood transfusion
Normalized name: Blood transfusion, auxiliary products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood transfusion at a speed of 2 ml/min (Group A)
Study: 4051254
Drug: Blood transfusion
Normalized name: Blood transfusion, auxiliary products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood transfusion at a speed of 5 ml/min (Group B)
Study: 31225739
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein pasta (10 g protein/serving)
Study: 31225739
Drug: Regular pasta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular pasta (7 g protein/serving)
Study: 27824398
Drug: Quercetin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (1 g daily for 12 weeks)
Study: 22085343
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (1500 to 2000 mg per day)
Study: 15042477
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment with conventional, new atypical or depot neuroleptics
Study: 15042477
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with conventional and depot neuroleptics
Study: 15042477
Drug: Clozapine or
Normalized name: clozapine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine or combination treatment with conventional and atypical neuroleptics
Study: 11755553
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone replacement therapy (HRT) with 17 beta-estradiol patches plus oral medroxyprogesterone acetate for 12 cycles of 28 days (group A)
Study: 9416252
Drug: Continuous lumbar
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous lumbar epidural block with morphine
Study: 8440099
Drug: CB0006 (anti-TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB0006 (anti-TNF monoclonal antibody) at various doses (0.1 mg/kg, 1.0 mg/kg, 10 mg/kg, or two doses of 1 mg/kg 24 hrs apart)
Study: 8440099
Drug: CB0006 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB0006 (high dose anti-TNF monoclonal antibody)
Study: 8440099
Drug: Standard supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard supportive care and antimicrobial therapy
Study: 3500735
Drug: Propofol 2.0‐2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.0‐2.5 mg kg‐1
Study: 3500735
Drug: Thiopentone 4‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 4‐5 mg kg‐1
Study: 29324496
Drug: Ultrasound-guided serratus
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided serratus plane block with 0.4 mL/kg of 0.375% ropivacaine
Study: 12663707
Drug: Interferon alfa-NL
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa-NL (Wellferon) given daily for 5 days every 3 weeks for up to 12 cycles
Study: 8653161
Drug: Intramuscular ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketorolac (administered 3.5 hours before procedure)
Study: 30730860
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rectal indomethacin and topical spray of epinephrine
Study: 29034576
Drug: 5-g curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-g curcumin
Study: 26627366
Drug: Clonazepam plus
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonazepam plus levetiracetam (2.5 g)
Study: 24930819
Drug: Mindfulness meditation
Normalized name: benzalkonium chloride Topical Foam [Meditize]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness meditation intervention (daily practice during Asian history course)
Study: 18165936
Drug: Methylcellulose pills
Normalized name: methylcellulose Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcellulose pills (2-week supply), told it was a cognitive enhancer
Study: 18165936
Drug: No pills
Normalized name: No Doz Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pills (control group)
Study: 25944628
Drug: Fasting serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting serum insulin
Study: 8205270
Drug: Fasting serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting serum insulin in Apo E 3/2 individuals
Study: 8205270
Drug: Fasting serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting serum insulin overall
Study: 11495173
Drug: Weight control
Normalized name: Daily-Vite Weight Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight control plus cognitive behavioral body image therapy
Study: 31560382
Drug: Daily low-quantity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily low-quantity drinking
Study: 30600956
Drug: Antihistamines and
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamines and atorvastatin
Study: 30600956
Drug: Antihistamines and
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamines and placebo
Study: 25350130
Drug: TFV 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFV 1% gel (40 mg TFV per 4 ml gel application)
Study: 25350130
Drug: Oral TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TDF (300 mg)
Study: 25350130
Drug: Hydroxyethyl‐cellulose (HEC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl‐cellulose (HEC) placebo gel
Study: 22035157
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg weekly (QW)
Study: 12366624
Drug: Preoperative supraphysiological
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative supraphysiological testosterone (600 mg T enanthate intramuscularly weekly for 4 weeks)
Study: 10404843
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 to 40 mg)
Study: 2119796
Drug: Preoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative administration of fenbufen
Study: 29251360
Drug: Therapeutic INR
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic INR on warfarin
Study: 29251360
Drug: Subtherapeutic INR
Normalized name: Inrebic
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subtherapeutic INR on warfarin
Study: 22429908
Drug: No anticoagulants
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulants
Study: 15286095
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 2-093 (200 mg bid)
Study: 15286095
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 2-093 (400 mg qd)
Study: 15286095
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 2-093 (800 mg qd)
Study: 15286095
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 2-093 (1200 mg qd)
Study: 8030593
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training with a diet providing 0.8 g protein.kg‐1.d‐1
Study: 8030593
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training with a diet providing 1.6 g protein.kg‐1.d‐1
Study: 2645063
Drug: Metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (200 mg b.i.d.)
Study: 28978332
Drug: Combination securement-dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination securement-dressing (CSD)
Study: 12701975
Drug: IV ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ketoprofen (100 mg)
Study: 9295178
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg Pergolide at bedtime
Study: 9295178
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg L-Dopa + Carbidopa
Study: 3080935
Drug: Transdermal nitroglycerin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin, 60 mg/24 h
Study: 28681394
Drug: Amenamevir 400
Normalized name: amenamevir
DrugBank: Amenamevir (DB11701)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Amenamevir 400 mg
Study: 28681394
Drug: Amenamevir 200
Normalized name: amenamevir
DrugBank: Amenamevir (DB11701)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Amenamevir 200 mg
Study: 28681394
Drug: Valaciclovir 1000
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 1000 mg three times daily (control)
Study: 25835379
Drug: TiF4 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TiF4 gel
Study: 25835379
Drug: TiF4 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TiF4 gel + CO2 laser
Study: 25835379
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel + CO2 laser
Study: 19727018
Drug: Creatine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (5 g of Cr + 15 g maltodextrin, 4 times a day for 5 days)
Study: 19727018
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 g maltodextrin, 4 times a day for 5 days)
Study: 18278530
Drug: Subcutaneous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ketamine treatment
Study: 10774786
Drug: Molsidomine 12
Normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine 12 mg orally for 48 hours
Study: 6402000
Drug: Dazoxiben 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dazoxiben 200 mg four times daily
Study: 22545088
Drug: ziprasidone (40-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: ziprasidone (40-160 mg/d)
Study: 20731496
Drug: Enhanced Outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Outpatient Treatment (EOT)
Study: 30971215
Drug: Continuing drug
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing drug treatment with ChEIs (with or without memantine)
Study: 30971215
Drug: Discontinuing drug
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuing drug treatment
Study: 21883424
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel with triester glycerol oxide (TGO)
Study: 21883424
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel without triester glycerol oxide (placebo)
Study: 15699240
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg daily for 14 days)
Study: 1853145
Drug: Nocloprost (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocloprost (100 micrograms/dose)
Study: 1853145
Drug: Aspirin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (2.5 g)
Study: 6348577
Drug: Preliminary volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preliminary volume expansion, vasodilators, and centrally acting drugs
Study: 6348577
Drug: Classical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical treatment for hypertension with a diuretic
Study: 30897031
Drug: Hypoxic CHO
Normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoxic CHO (HCHO; 6% CHO provided as 2 ml/kg/15 min; FiO2 = 16.3%)
Study: 20355225
Drug: Measurement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of insulin-like growth factor-I (IGF-I) and type III pro-collagen (P-III-P) as markers of GH action
Study: 17088488
Drug: Ritonavir (RTV)
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir (RTV) 200 mg QD
Study: 17088488
Drug: Ritonavir (RTV)
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir (RTV) 100 mg QD